Anti-Apolipoprotein E antibody (ab85311)

Overview

  • Product nameAnti-Apolipoprotein E antibody
    See all Apolipoprotein E primary antibodies
  • Description
    Rabbit polyclonal to Apolipoprotein E
  • Tested applicationsWBmore details
  • Species reactivity
    Reacts with: Human
    Predicted to work with: Sheep, Chimpanzee, Gorilla, Orangutan
  • Immunogen

    Synthetic peptide conjugated to KLH derived from within residues 250 to the C-terminus of Human Apolipoprotein E .

    (Peptide available as ab93496.)

  • Positive control
    • This antibody gave a positive signal in human plasma total protein.

Applications

Our Abpromise guarantee covers the use of ab85311 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB
  • Application notesWB: Use at a concentration of 1 µg/ml. Detects a band of approximately 36 kDa (predicted molecular weight: 36 kDa).
    Not yet tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • Target

    • FunctionMediates the binding, internalization, and catabolism of lipoprotein particles. It can serve as a ligand for the LDL (apo B/E) receptor and for the specific apo-E receptor (chylomicron remnant) of hepatic tissues.
    • Tissue specificityOccurs in all lipoprotein fractions in plasma. It constitutes 10-20% of very low density lipoproteins (VLDL) and 1-2% of high density lipoproteins (HDL). APOE is produced in most organs. Significant quantities are produced in liver, brain, spleen, lung, adrenal, ovary, kidney and muscle.
    • Involvement in diseaseDefects in APOE are a cause of hyperlipoproteinemia type 3 (HLPP3) [MIM:107741]; also known as familial dysbetalipoproteinemia. Individuals with HLPP3 are clinically characterized by xanthomas, yellowish lipid deposits in the palmar crease, or less specific on tendons and on elbows. The disorder rarely manifests before the third decade in men. In women, it is usually expressed only after the menopause. The vast majority of the patients are homozygous for APOE*2 alleles. More severe cases of HLPP3 have also been observed in individuals heterozygous for rare APOE variants. The influence of APOE on lipid levels is often suggested to have major implications for the risk of coronary artery disease (CAD). Individuals carrying the common APOE*4 variant are at higher risk of CAD.
      Genetic variations in APOE are associated with Alzheimer disease type 2 (AD2) [MIM:104310]. It is a late-onset neurodegenerative disorder characterized by progressive dementia, loss of cognitive abilities, and deposition of fibrillar amyloid proteins as intraneuronal neurofibrillary tangles, extracellular amyloid plaques and vascular amyloid deposits. The major constituent of these plaques is the neurotoxic amyloid-beta-APP 40-42 peptide (s), derived proteolytically from the transmembrane precursor protein APP by sequential secretase processing. The cytotoxic C-terminal fragments (CTFs) and the caspase-cleaved products such as C31 derived from APP, are also implicated in neuronal death. Note=The APOE*4 allele is genetically associated with the common late onset familial and sporadic forms of Alzheimer disease. Risk for AD increased from 20% to 90% and mean age at onset decreased from 84 to 68 years with increasing number of APOE*4 alleles in 42 families with late onset AD. Thus APOE*4 gene dose is a major risk factor for late onset AD and, in these families, homozygosity for APOE*4 was virtually sufficient to cause AD by age 80. The mechanism by which APOE*4 participates in pathogenesis is not known.
      Defects in APOE are a cause of sea-blue histiocyte disease (SBHD) [MIM:269600]; also known as sea-blue histiocytosis. This disorder is characterized by splenomegaly, mild thrombocytopenia and, in the bone marrow, numerous histiocytes containing cytoplasmic granules which stain bright blue with the usual hematologic stains. The syndrome is the consequence of an inherited metabolic defect analogous to Gaucher disease and other sphingolipidoses.
      Defects in APOE are a cause of lipoprotein glomerulopathy (LPG) [MIM:611771]. LPG is an uncommon kidney disease characterized by proteinuria, progressive kidney failure, and distinctive lipoprotein thrombi in glomerular capillaries. It mainly affects people of Japanese and Chinese origin. The disorder has rarely been described in Caucasians.
    • Sequence similaritiesBelongs to the apolipoprotein A1/A4/E family.
    • Post-translational
      modifications
      Synthesized with the sialic acid attached by O-glycosidic linkage and is subsequently desialylated in plasma. O-glycosylated with core 1 or possibly core 8 glycans. Thr-307 is a minor glycosylation site compared to Ser-308.
      Glycated in plasma VLDL of normal subjects, and of hyperglycemic diabetic patients at a higher level (2-3 fold).
      Phosphorylation sites are present in the extracelllular medium.
    • Cellular localizationSecreted.
    • Information by UniProt
    • Database links
    • Alternative names
      • AD2 antibody
      • Apo-E antibody
      • ApoE antibody
      • APOE_HUMAN antibody
      • APOEA antibody
      • Apolipoprotein E antibody
      • Apolipoprotein E3 antibody
      • ApolipoproteinE antibody
      • Apoprotein antibody
      • LDLCQ5 antibody
      • LPG antibody
      see all

    Anti-Apolipoprotein E antibody images

    • Anti-Apolipoprotein E antibody (ab85311) at 1 µg/ml + Human Plasma Total Protein Lysate at 10 µg

      Secondary
      Goat polyclonal to Rabbit IgG - H&L - Pre-Adsorbed (HRP) at 1/3000 dilution
      developed using the ECL technique

      Performed under reducing conditions.

      Predicted band size : 36 kDa
      Observed band size : 36 kDa


      Exposure time : 20 minutes
    • Anti-Apolipoprotein E antibody (ab85311) at 1 µg/ml + Human Apolipoprotein E full length protein (ab55210) at 0.1 µg

      Secondary
      Goat Anti-Rabbit IgG H&L (HRP) preadsorbed (ab97080) at 1/5000 dilution
      developed using the ECL technique

      Performed under reducing conditions.

      Exposure time : 4 minutes

    References for Anti-Apolipoprotein E antibody (ab85311)

    ab85311 has not yet been referenced specifically in any publications.

    Product Wall

    Application Western blot
    Sample Mouse Tissue lysate - whole (Brain, Serum and Liver)
    Loading amount 20 µg
    Specification Brain, Serum and Liver
    Gel Running Conditions Reduced Denaturing (12)
    Blocking step Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5%
    Username

    Dr. Ruma Raha-Chowdhury

    Verified customer

    Submitted Aug 13 2012

    Application Immunohistochemistry (PFA perfusion fixed frozen sections)
    Sample Mouse Tissue sections (Brain section)
    Specification Brain section
    Fixative Paraformaldehyde
    Permeabilization Yes - 0.1% TritonX in 0.1% PBS
    Blocking step Serum as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 10% · Temperature: 24°C
    Username

    Dr. Ruma Raha-Chowdhury

    Verified customer

    Submitted Aug 13 2012

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"